Ostarine would be the closest SARM to becoming authorized in drugs and is at present in phase II medical trials. Like SARMs usually, MK-2866 targets androgen receptors on the selective foundation and avoids making the sorts of dangerous side effects involved with substances like testosterone, human growth hormone, or anabolic steroids, for example